Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains
Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Covid Vaccine | COVID-19 | Influenza | Influenza Vaccine | Pfizer | Pharmaceuticals | SARS | Study | Vaccines